Physician profile
Mara Sterio
NPI 1215939822
$686.06
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $162 · 2021: $84.27 · 2022: $55.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $184.33 | 2019-2020 | |
| Sobi, INC | $98.25 | 2019-2022 | |
| Genentech USA, INC. | $70.36 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $54.33 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $44.61 | 2019-2021 | |
| Neos Therapeutics, LP | $43.55 | 2019-2020 | |
| Adlon Therapeutics L.P. | $36.07 | 2019-2020 | |
| Aytu Biopharma, INC. | $15.52 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.81 | 2019 | |
| Corium, LLC | $14.74 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $13.71 | 2020 | |
| Glaxosmithkline, LLC. | $13.19 | 2019 | |
| Kaleo, INC. | $12.35 | 2022 | |
| Cranial Technologies, INC | $11.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Sterio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.